Find uplifting stories about heroes, innovations, and solutions
92 results for "pancreatic cancer"
For the first time in years, doctors have a promising new weapon against one of the deadliest cancers. A targeted therapy that blocks specific gene mutations is bringing fresh hope to pancreatic cancer patients and their families.
Thirty cancer survivors and their families gathered in Killeen, Texas to celebrate hope, resilience, and the community that helps them fight. One survivor who beat pancreatic cancer shared his powerful message: never lose hope.
An experimental once-daily pill nearly doubled survival time for patients with advanced pancreatic cancer, offering hope for one of the deadliest forms of the disease. The breakthrough targets a mutation present in over 90% of pancreatic tumors that scientists have struggled to treat for four decades.
Scientists have finally cracked a genetic mutation once thought impossible to treat, potentially transforming outcomes for 90% of pancreatic cancer patients. A new drug targeting KRAS mutations has doubled survival time compared to traditional chemotherapy.
A breakthrough drug targeting previously "undruggable" KRAS mutations has approximately doubled survival time for metastatic pancreatic cancer patients compared to chemotherapy. The development marks a historic shift for a disease that affects over 90% of pancreatic cancer cases. --- ##
A revolutionary drug just doubled survival time for patients with advanced pancreatic cancer, one of the deadliest forms of the disease. Doctors are calling it unprecedented, and the breakthrough could soon help patients with lung, colorectal, and other cancers too.
A breakthrough treatment for pancreatic cancer shows promise in doubling how long patients survive with one of the deadliest forms of cancer. This medical advance offers new hope for thousands of families facing this devastating diagnosis.
An experimental pill called daraxonrasib helped pancreatic cancer patients live nearly twice as long as those on standard chemotherapy. The breakthrough results, presented at a major cancer conference, mark a historic first for one of medicine's toughest cancers.
A breakthrough drug called daraxonrasib doubled survival time for pancreatic cancer patients compared to chemotherapy, offering new hope for one of the deadliest cancers. The treatment targets the genetic mutation behind 90% of pancreatic cancers and causes far fewer severe side effects.
An experimental pancreatic cancer treatment that helped patients live nearly twice as long as standard chemotherapy is now reaching patients before formal FDA approval. Revolution Medicines began shipping daraxonrasib to physicians this week through a special early access program.
A new pill targeting the KRAS mutation doubles survival time in pancreatic cancer patients, marking the biggest treatment breakthrough ever for one of the world's deadliest cancers. After 25 years of research and $17 million in funding, scientists are finally seeing progress on multiple fronts at once.
A daily pill called daraxonrasib helped control cancer in 90% of pancreatic cancer patients during early trials, offering new hope for a disease that has had few effective treatments. The drug targets genetic mutations found in over 90% of pancreatic cancers.
A breakthrough drug for pancreatic cancer has stunned researchers by controlling disease in 90% of patients who had already tried chemotherapy. The daily pill targets gene mutations found in nearly all pancreatic cancers, offering hope where treatment options have been scarce.
Researchers discovered that a cancer protein not only fuels tumor growth but also helps cancer cells repair damage from chemotherapy. The finding could transform treatment for pancreatic cancer and other aggressive tumors.
Researchers discovered that pancreatic cancer cells depend on inflammation from damaged mitochondria to survive, and blocking this process kills tumors. The breakthrough could finally offer new treatment options for one of the deadliest cancers.
A breakthrough pill is helping pancreatic cancer patients live three to four times longer than with chemotherapy alone. Vicky Stinson, given months to live in 2024, is now thriving two years later thanks to the new treatment.
A breakthrough drug that targets the genetic mutation driving 90% of pancreatic cancers has been authorized for expanded access by the FDA. Patients are seeing their cancer stabilized for months longer than expected, with some feeling better within days.
Scientists in Ireland have created the first complete "playbook" of pancreatic cancer, revealing why it's been so deadly and where new treatments could finally work. Their breakthrough approach targets multiple weak points at once, offering fresh hope for a disease that has resisted progress for decades.
A breakthrough drug called daraxonrasib has doubled survival time for patients with advanced pancreatic cancer, targeting a protein scientists thought was impossible to stop. The FDA has already fast-tracked the treatment, offering new hope for a disease that gives most patients less than a year to live.
A new AI system from Mayo Clinic can spot pancreatic cancer on routine CT scans up to three years before doctors typically diagnose it, when the disease is still treatable. The breakthrough could transform survival rates for one of the deadliest cancers.
Showing 20 of 92